Switch theme
Sign up to access all valuation multiples
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
1998
n/a
LTM Revenue $498M
LTM EBITDA $127M
$4.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gan & Lee Pharmaceuticals has a last 12-month revenue (LTM) of $498M and a last 12-month EBITDA of $127M.
In the most recent fiscal year, Gan & Lee Pharmaceuticals achieved revenue of $423M and an EBITDA of $123M.
Gan & Lee Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gan & Lee Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $498M | XXX | $423M | XXX | XXX | XXX |
| Gross Profit | $385M | XXX | $316M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $127M | XXX | $123M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $105M | XXX | $43.1M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $114M | XXX | $85.3M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gan & Lee Pharmaceuticals's stock price is CNY 55 (or $8).
Gan & Lee Pharmaceuticals has current market cap of CNY 32.8B (or $4.5B), and EV of CNY 30.4B (or $4.2B).
See Gan & Lee Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.2B | $4.5B | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gan & Lee Pharmaceuticals has market cap of $4.5B and EV of $4.2B.
Gan & Lee Pharmaceuticals's trades at 10.0x EV/Revenue multiple, and 34.2x EV/EBITDA.
Equity research analysts estimate Gan & Lee Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gan & Lee Pharmaceuticals has a P/E ratio of 39.7x.
See valuation multiples for Gan & Lee Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.5B | XXX | $4.5B | XXX | XXX | XXX |
| EV (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV/Revenue | 8.5x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBITDA | 33.3x | XXX | 34.2x | XXX | XXX | XXX |
| EV/EBIT | 40.1x | XXX | 97.8x | XXX | XXX | XXX |
| EV/Gross Profit | 11.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 39.7x | XXX | 53.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 315.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGan & Lee Pharmaceuticals's last 12 month revenue growth is 31%
Gan & Lee Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Gan & Lee Pharmaceuticals's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gan & Lee Pharmaceuticals's rule of X is 104% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gan & Lee Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 75% | XXX | 65% | XXX | XXX | XXX |
| Rule of 40 | 52% | XXX | 61% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 104% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gan & Lee Pharmaceuticals acquired XXX companies to date.
Last acquisition by Gan & Lee Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Gan & Lee Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gan & Lee Pharmaceuticals founded? | Gan & Lee Pharmaceuticals was founded in 1998. |
| Where is Gan & Lee Pharmaceuticals headquartered? | Gan & Lee Pharmaceuticals is headquartered in China. |
| Is Gan & Lee Pharmaceuticals publicy listed? | Yes, Gan & Lee Pharmaceuticals is a public company listed on SHG. |
| What is the stock symbol of Gan & Lee Pharmaceuticals? | Gan & Lee Pharmaceuticals trades under 603087 ticker. |
| When did Gan & Lee Pharmaceuticals go public? | Gan & Lee Pharmaceuticals went public in 2020. |
| Who are competitors of Gan & Lee Pharmaceuticals? | Similar companies to Gan & Lee Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Gan & Lee Pharmaceuticals? | Gan & Lee Pharmaceuticals's current market cap is $4.5B |
| What is the current revenue of Gan & Lee Pharmaceuticals? | Gan & Lee Pharmaceuticals's last 12 months revenue is $498M. |
| What is the current revenue growth of Gan & Lee Pharmaceuticals? | Gan & Lee Pharmaceuticals revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Gan & Lee Pharmaceuticals? | Current revenue multiple of Gan & Lee Pharmaceuticals is 8.5x. |
| Is Gan & Lee Pharmaceuticals profitable? | Yes, Gan & Lee Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gan & Lee Pharmaceuticals? | Gan & Lee Pharmaceuticals's last 12 months EBITDA is $127M. |
| What is Gan & Lee Pharmaceuticals's EBITDA margin? | Gan & Lee Pharmaceuticals's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Gan & Lee Pharmaceuticals? | Current EBITDA multiple of Gan & Lee Pharmaceuticals is 33.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
